GTx, Inc. Announces Release of Fourth Quarter and 2004 Fiscal Year Financial Results, Conference Call and Webcast

MEMPHIS, Tenn., February 3 -- GTx, Inc. (Nasdaq: GTXI), a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily related to the treatment of serious men's health conditions, today announced that it will host a conference call and webcast to discuss the Company’s fourth quarter and 2004 fiscal year financial results on Wednesday, February 16, 2005 at 10:00 a.m., Eastern Time. The call and webcast will follow the release of the fourth quarter and 2004 fiscal year financial results earlier that day.

To listen to the conference call, please dial 800-291-9234 from the United States or Canada or 617-614-3923 from outside North America. The access code for the call is 71909405. A playback of the call will be available from approximately 12:00 p.m., Eastern Time, on February 16 through March 2, 2005 and may be accessed by dialing 888-286-8010 from the United States or Canada or 617-801-6888 from outside North America, and referencing reservation number 74169468. Additionally, you may access the live and subsequently archived webcast of the conference call from the Investor Relations section of the Company’s website at http://www.gtxinc.com.

About GTx

GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for serious men's health conditions. GTx's drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx currently has four clinical programs. In two of the clinical programs, the company is developing ACAPODENE™, its most advanced product candidate, through clinical trials for two separate indications: (1) a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men and (2) a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer. In its third clinical program, GTx and its partner, Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, are developing andarine, a selective androgen receptor modulator (SARM), which is expected to enter a Phase II clinical trial in 2005. In its fourth clinical program, GTx is developing its own SARM, ostarine, for andropause and other conditions related to aging, including sarcopenia. In addition, GTx has a deep pipeline generated from its own discovery program which includes specific preclinical product candidates prostarine, a SARM, for benign prostatic hyperplasia (BPH), and andromustine, an anticancer drug, for hormone refractory prostate cancer.